Kousuke Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kousuke Watanabe has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Hidenori Kage
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
20 shared publications Takahide Nagase
Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan
17 shared publicationsNobuya Ohishi
Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo
14 shared publicationsHidenori Kage
Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan
13 shared publications- Katsutoshi Oda
Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
13 shared publications - Jun Nakajima
Department of Thoracic Surgery, The University of Tokyo Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
12 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in SSRN Electronic Journal
Therapeutic Yield of Comprehensive Genomic Profiling After Osimertinib Discontinuation in EGFR-Mutated Non–Small Cell Lung Cancer
Background: Comprehensive genomic profiling (CGP) after osimertinib may identify potentially targetable resistance-associated alterations in patients with EGFR-mutated non–small cell lung cancer (NSCLC). However, their translation into genotype-matched treatment in routine clinical practice remains unclear.Patients and Methods: We retrospectively analyzed patients with EGFR-mutated NSCLC in Japan’s nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database who underwent CGP after osimertinib discontinuation. Potentially targetable non-EGFR alterations were prespecified. We assessed their detection, expert-panel (EP) recommendations, treatment implementation, and genotype matching. Factors associated with detection were evaluated using multivariable logistic regression.Results: Among 477 patients, potentially targetable non-EGFR alterations were identified in 73 (15.3%). An EP therapeutic option was presented for 56 (76.7%), and an EP-presented therapy was administered in 21 (28.8%). Genotype-matched non-EGFR therapy was administered in 15 patients (20.5% of those with a potentially targetable alteration; 3.1% overall). Genotype-matched therapy was administered to 5 of 7 patients (71.4%) with BRAF V600 alterations and 5 of 6 (83.3%) with RET rearrangements, but only 1 of 37 (2.7%) with MET amplification and 1 of 18 (5.6%) with ERBB2 amplification. Tissue-based CGP was associated with a higher likelihood of detecting potentially targetable non-EGFR alterations than liquid-based CGP (adjusted odds ratio, 4.07; 95% confidence interval, 2.32–7.14; P < 0.001).Conclusions: CGP after osimertinib discontinuation identified potentially targetable non-EGFR alterations in a subset of patients, but only a small proportion received genotype-matched therapy. The therapeutic yield may depend not only on target detection but also on translation into genotype-matched treatment in routine clinical practice.
- 30 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTherapeutic Yield of Comprehensive Genomic Profiling After Osimertinib Discontinuation in EGFR-Mutated Non–Small Cell Lung Cancer
Background: Comprehensive genomic profiling (CGP) after osimertinib may identify potentially targetable resistance-associated alterations in patients with EGFR-mutated non–small cell lung cancer (NSCLC). However, their translation into genotype-matched treatment in routine clinical practice remains unclear.Patients and Methods: We retrospectively analyzed patients with EGFR-mutated NSCLC in Japan’s nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database who underwent CGP after osimertinib discontinuation. Potentially targetable non-EGFR alterations were prespecified. We assessed their detection, expert-panel (EP) recommendations, treatment implementation, and genotype matching. Factors associated with detection were evaluated using multivariable logistic regression.Results: Among 477 patients, potentially targetable non-EGFR alterations were identified in 73 (15.3%). An EP therapeutic option was presented for 56 (76.7%), and an EP-presented therapy was administered in 21 (28.8%). Genotype-matched non-EGFR therapy was administered in 15 patients (20.5% of those with a potentially targetable alteration; 3.1% overall). Genotype-matched therapy was administered to 5 of 7 patients (71.4%) with BRAF V600 alterations and 5 of 6 (83.3%) with RET rearrangements, but only 1 of 37 (2.7%) with MET amplification and 1 of 18 (5.6%) with ERBB2 amplification. Tissue-based CGP was associated with a higher likelihood of detecting potentially targetable non-EGFR alterations than liquid-based CGP (adjusted odds ratio, 4.07; 95% confidence interval, 2.32–7.14; P < 0.001).Conclusions: CGP after osimertinib discontinuation identified potentially targetable non-EGFR alterations in a subset of patients, but only a small proportion received genotype-matched therapy. The therapeutic yield may depend not only on target detection but also on translation into genotype-matched treatment in routine clinical practice.
- Open Access
- 7 October 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-11
Bridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan
Background: Genomic testing has become increasingly important in prostate cancer because BRCA1/2 and other genomic alterations can inform treatment selection and may indicate an underlying hereditary cancer syndrome. However, treatment-directed testing does not necessarily lead to genetic counseling, germline genetic testing, cascade testing, or familial risk management. Prostate cancer therefore presents a unique implementation challenge, particularly in tumor-first testing pathways. Methods: We conducted a narrative review of international literature on barriers to germline genetic testing and genetic counseling in prostate cancer, an environmental scan of publicly available Japanese sources, and targeted international comparisons of genetics specialist workforce and academic visibility. The findings were integrated into a logic model for hereditary cancer care implementation. Results: International evidence identified multilevel barriers, including variation in genetic knowledge and training opportunities among urologists, difficulty identifying eligible patients, communication and workflow constraints, limited access to genetics services, financial barriers, low patient awareness, and psychosocial and gender-related factors. The Japanese environmental scan indicated incomplete linkage from tumor genomic testing to genetic counseling, underrepresentation of urologists among genetics specialists, low academic visibility, and limited emphasis on familial risk management in patient materials, guidelines, and education. The logic model highlighted family history assessment, recognition of tumor-first genomic findings, embedded referral pathways, and patient-centered information support as key intervention points. Conclusions: The implementation gap reflects a structural disconnect between prostate cancer genomics and hereditary cancer care. Pathway redesign may help link tumor genomic testing with germline genetic testing and familial risk management.
- 7 October 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-11
Open AccessBridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan
Background: Genomic testing has become increasingly important in prostate cancer because BRCA1/2 and other genomic alterations can inform treatment selection and may indicate an underlying hereditary cancer syndrome. However, treatment-directed testing does not necessarily lead to genetic counseling, germline genetic testing, cascade testing, or familial risk management. Prostate cancer therefore presents a unique implementation challenge, particularly in tumor-first testing pathways. Methods: We conducted a narrative review of international literature on barriers to germline genetic testing and genetic counseling in prostate cancer, an environmental scan of publicly available Japanese sources, and targeted international comparisons of genetics specialist workforce and academic visibility. The findings were integrated into a logic model for hereditary cancer care implementation. Results: International evidence identified multilevel barriers, including variation in genetic knowledge and training opportunities among urologists, difficulty identifying eligible patients, communication and workflow constraints, limited access to genetics services, financial barriers, low patient awareness, and psychosocial and gender-related factors. The Japanese environmental scan indicated incomplete linkage from tumor genomic testing to genetic counseling, underrepresentation of urologists among genetics specialists, low academic visibility, and limited emphasis on familial risk management in patient materials, guidelines, and education. The logic model highlighted family history assessment, recognition of tumor-first genomic findings, embedded referral pathways, and patient-centered information support as key intervention points. Conclusions: The implementation gap reflects a structural disconnect between prostate cancer genomics and hereditary cancer care. Pathway redesign may help link tumor genomic testing with germline genetic testing and familial risk management.
- Open Access
- 15 September 2026
- Published by Elsevier in Lung Cancer
- Vol. 221
Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC
- 15 September 2026
- Published by Elsevier in Lung Cancer
- Vol. 221
Open AccessStandard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC
- Open Access
- 9 July 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (4) , e70223
Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on NF1 Gene Mutation
Introduction: Neurofibromatosis type 1 (NF1) is a genetic disorder that increases the risk of various tumors. However, its association with testicular germ cell tumors (GCTs) is rare. We report a case of metastatic GCT in an NF1 patient treated with precision medicine. Case Presentation: A 40‐year‐old male with NF1 presented with a left testicular non‐seminomatous GCT and lung metastases. The tumor showed progressive disease after chemotherapy (VIP, TGP) and surgical removal of metastases. Comprehensive genomic profiling (CGP) test found a pathogenic NF1 frameshift mutation (p.Q514fs*43). Based on this finding, the patient received the MEK inhibitor trametinib under patient‐proposed healthcare services (BELIEVE Trial). Treatment resulted in normalization of serum alpha‐fetoprotein (AFP) for 6 months before the tumor eventually progressed. The patient died at 39 months after diagnosis. Conclusion: This is the first report of trametinib for a metastatic GCT with an NF1 mutation, suggesting a possible but limited treatment effect. Trial Registration: The prospective trial of patient‐proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE), NCCH1901/jRCTs031190104
- 9 July 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (4) , e70223
Open AccessMetastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on NF1 Gene Mutation
Introduction: Neurofibromatosis type 1 (NF1) is a genetic disorder that increases the risk of various tumors. However, its association with testicular germ cell tumors (GCTs) is rare. We report a case of metastatic GCT in an NF1 patient treated with precision medicine. Case Presentation: A 40‐year‐old male with NF1 presented with a left testicular non‐seminomatous GCT and lung metastases. The tumor showed progressive disease after chemotherapy (VIP, TGP) and surgical removal of metastases. Comprehensive genomic profiling (CGP) test found a pathogenic NF1 frameshift mutation (p.Q514fs*43). Based on this finding, the patient received the MEK inhibitor trametinib under patient‐proposed healthcare services (BELIEVE Trial). Treatment resulted in normalization of serum alpha‐fetoprotein (AFP) for 6 months before the tumor eventually progressed. The patient died at 39 months after diagnosis. Conclusion: This is the first report of trametinib for a metastatic GCT with an NF1 mutation, suggesting a possible but limited treatment effect. Trial Registration: The prospective trial of patient‐proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE), NCCH1901/jRCTs031190104
- Open Access
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Standard Targeted Therapy Implementation for Driver Alterations Newly Identified by Comprehensive Genomic Profiling in Clinically Driver-Negative Advanced NSCLC
Background: Comprehensive genomic profiling (CGP) can identify oncogenic drivers missed by routine molecular testing in advanced or recurrent non-small cell lung cancer (NSCLC). However, the availability of standard targeted therapy, treatment implementation, and survival relevance of these CGP-identified new drivers remain unclear.Methods: Using the nationwide Center for Cancer Genomics and Advanced Therapeutics database, we analyzed patients with advanced or recurrent NSCLC without clinically known driver alterations before CGP. CGP-identified new drivers were classified as actionable or non-actionable according to standard targeted therapy availability in Japan. We evaluated prevalence, treatment implementation, and overall survival (OS) from CGP registration.Results: Among 2,296 patients, 855 had CGP-identified new drivers, of whom 495 (57.9%) had actionable alterations. Matched targeted therapy was administered to 191 patients with actionable alterations (38.6%) and to 84.5% of those with documented post-CGP systemic therapy. Median OS was longest in patients with actionable CGP-identified new drivers, followed by driver-negative patients and those with non-actionable CGP-identified new drivers (18.9, 11.4, and 10.2 months, respectively; log-rank P < 0.001). In multivariable analysis, actionable CGP-identified new drivers were associated with longer OS than driver-negative status (adjusted hazard ratio, 0.71; 95% confidence interval, 0.59–0.84; P < 0.001), whereas non-actionable new drivers were not. Sensitivity analyses using time-specific drug-availability definitions yielded consistent findings.Conclusions: CGP identified new drivers with available standard targeted therapy in patients with advanced or recurrent NSCLC. The clinical relevance of CGP-identified new driver detection appears linked to standard targeted therapy availability and translation of actionable findings into matched therapy.
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessStandard Targeted Therapy Implementation for Driver Alterations Newly Identified by Comprehensive Genomic Profiling in Clinically Driver-Negative Advanced NSCLC
Background: Comprehensive genomic profiling (CGP) can identify oncogenic drivers missed by routine molecular testing in advanced or recurrent non-small cell lung cancer (NSCLC). However, the availability of standard targeted therapy, treatment implementation, and survival relevance of these CGP-identified new drivers remain unclear.Methods: Using the nationwide Center for Cancer Genomics and Advanced Therapeutics database, we analyzed patients with advanced or recurrent NSCLC without clinically known driver alterations before CGP. CGP-identified new drivers were classified as actionable or non-actionable according to standard targeted therapy availability in Japan. We evaluated prevalence, treatment implementation, and overall survival (OS) from CGP registration.Results: Among 2,296 patients, 855 had CGP-identified new drivers, of whom 495 (57.9%) had actionable alterations. Matched targeted therapy was administered to 191 patients with actionable alterations (38.6%) and to 84.5% of those with documented post-CGP systemic therapy. Median OS was longest in patients with actionable CGP-identified new drivers, followed by driver-negative patients and those with non-actionable CGP-identified new drivers (18.9, 11.4, and 10.2 months, respectively; log-rank P < 0.001). In multivariable analysis, actionable CGP-identified new drivers were associated with longer OS than driver-negative status (adjusted hazard ratio, 0.71; 95% confidence interval, 0.59–0.84; P < 0.001), whereas non-actionable new drivers were not. Sensitivity analyses using time-specific drug-availability definitions yielded consistent findings.Conclusions: CGP identified new drivers with available standard targeted therapy in patients with advanced or recurrent NSCLC. The clinical relevance of CGP-identified new driver detection appears linked to standard targeted therapy availability and translation of actionable findings into matched therapy.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2600100
Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations
PURPOSE: Methylthioadenosine phosphorylase ( MTAP ) deletion represents a promising therapeutic vulnerability through synthetic lethality. However, the clinical and molecular context of MTAP -deleted thoracic tumors, particularly with respect to actionable oncogenic drivers and immune checkpoint inhibitor efficacy, remains incompletely defined across diverse populations. METHODS: We analyzed clinicogenomic data from two nationwide cohorts: AACR Project GENIE (United States; n = 11,091 evaluable samples) and Center for Cancer Genomics and Advanced Therapeutics (C-CAT; Japan; n = 4,851). MTAP copy number was assessed in lung, pleural, and thymic tumors. We evaluated histology-specific prevalence, comutational patterns, associations with actionable genomic alterations, tumor mutational burden (TMB), and overall survival (OS) in selected molecular subgroups. RESULTS: In lung cancer, MTAP deletion occurred at comparable frequencies between adenocarcinoma and squamous cell carcinoma within each cohort (GENIE: 8.1% v 9.8%; C-CAT: 19.6% v 16.5%) but was rare in small cell lung cancer (GENIE: 1.0%; C-CAT: 1.9%). In thymic tumors, MTAP deletion was observed predominantly in thymic carcinoma and was uncommon in thymoma. MTAP deletion was strongly associated with CDKN2A/B deletions and was rare in their absence. MTAP deletion frequently coexisted with actionable driver alterations, including EGFR mutations, ALK fusions, and ERBB2 alterations. A robust inverse association with RB1 mutations was observed in both cohorts. Although MTAP deletion appeared associated with lower TMB ( P < .01) and shorter OS in EGFR -mutated lung cancer (median 18.5 v 31.4 months, P < .01), these associations were largely attributable to enrichment of oncogenic drivers and concurrent CDKN2A loss, respectively. CONCLUSION: MTAP -deleted thoracic tumors exhibit reproducible clinical and molecular features across populations. Our findings support the rational, globally applicable development of MTAP -targeted synthetic lethal strategies in thoracic malignancies, particularly in combination with molecular targeted agents.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2600100
Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations
PURPOSE: Methylthioadenosine phosphorylase ( MTAP ) deletion represents a promising therapeutic vulnerability through synthetic lethality. However, the clinical and molecular context of MTAP -deleted thoracic tumors, particularly with respect to actionable oncogenic drivers and immune checkpoint inhibitor efficacy, remains incompletely defined across diverse populations. METHODS: We analyzed clinicogenomic data from two nationwide cohorts: AACR Project GENIE (United States; n = 11,091 evaluable samples) and Center for Cancer Genomics and Advanced Therapeutics (C-CAT; Japan; n = 4,851). MTAP copy number was assessed in lung, pleural, and thymic tumors. We evaluated histology-specific prevalence, comutational patterns, associations with actionable genomic alterations, tumor mutational burden (TMB), and overall survival (OS) in selected molecular subgroups. RESULTS: In lung cancer, MTAP deletion occurred at comparable frequencies between adenocarcinoma and squamous cell carcinoma within each cohort (GENIE: 8.1% v 9.8%; C-CAT: 19.6% v 16.5%) but was rare in small cell lung cancer (GENIE: 1.0%; C-CAT: 1.9%). In thymic tumors, MTAP deletion was observed predominantly in thymic carcinoma and was uncommon in thymoma. MTAP deletion was strongly associated with CDKN2A/B deletions and was rare in their absence. MTAP deletion frequently coexisted with actionable driver alterations, including EGFR mutations, ALK fusions, and ERBB2 alterations. A robust inverse association with RB1 mutations was observed in both cohorts. Although MTAP deletion appeared associated with lower TMB ( P < .01) and shorter OS in EGFR -mutated lung cancer (median 18.5 v 31.4 months, P < .01), these associations were largely attributable to enrichment of oncogenic drivers and concurrent CDKN2A loss, respectively. CONCLUSION: MTAP -deleted thoracic tumors exhibit reproducible clinical and molecular features across populations. Our findings support the rational, globally applicable development of MTAP -targeted synthetic lethal strategies in thoracic malignancies, particularly in combination with molecular targeted agents.
- Open Access
- 31 March 2026
- Published by Elsevier in SSRN Electronic Journal
TP53 Mutation Subtypes and Outcomes with First-Line EGFR-TKI Monotherapy in EGFR-mutant Non-Small Cell Lung Cancer: A Nationwide C-CAT Analysis
Background: Outcomes with first-line EGFR tyrosine kinase inhibitors (EGFR-TKIs) vary in EGFR-mutant advanced non–small cell lung cancer (NSCLC). We investigated clinicogenomic prognostic factors in a nationwide real-world cohort, focusing on TP53 and TP53 mutation subtypes.Methods: Using the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, we identified patients registered between June 2019 and January 2026 with EGFR exon 19 deletion or L858R who received first-line EGFR-TKI monotherapy (N = 521). The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS). Associations were evaluated using multivariable Cox models. Sensitivity analyses examined tissue-based and third-generation EGFR-TKI subsets. TP53 variants were classified as gain-of-function (GOF) hotspot missense, truncating, or other non-truncating.Results: TP53 mutations were independently associated with shorter PFS (adjusted hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.04–1.62; p = 0.019) and shorter OS in Kaplan–Meier analyses (median, 61.7 vs 91.4 months; p < 0.001). In sensitivity analyses, the association persisted in the tissue-based subset (adjusted HR, 1.55; p = 0.008), and the trend was consistent in the third-generation EGFR-TKI subset (adjusted HR, 1.26; p = 0.088). In subtype analyses, GOF and other non-truncating TP53 mutations were associated with shorter PFS (adjusted HR 1.43, p = 0.046 and 1.36, p = 0.013, respectively), whereas truncating variants were not (adjusted HR 1.03, p = 0.258).Conclusion: In EGFR-mutant NSCLC treated with first-line EGFR-TKI monotherapy, TP53 mutations—particularly GOF and non-truncating subtypes—were associated with poorer PFS and OS, supporting TP53-informed prognostic stratification.
- 31 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTP53 Mutation Subtypes and Outcomes with First-Line EGFR-TKI Monotherapy in EGFR-mutant Non-Small Cell Lung Cancer: A Nationwide C-CAT Analysis
Background: Outcomes with first-line EGFR tyrosine kinase inhibitors (EGFR-TKIs) vary in EGFR-mutant advanced non–small cell lung cancer (NSCLC). We investigated clinicogenomic prognostic factors in a nationwide real-world cohort, focusing on TP53 and TP53 mutation subtypes.Methods: Using the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, we identified patients registered between June 2019 and January 2026 with EGFR exon 19 deletion or L858R who received first-line EGFR-TKI monotherapy (N = 521). The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS). Associations were evaluated using multivariable Cox models. Sensitivity analyses examined tissue-based and third-generation EGFR-TKI subsets. TP53 variants were classified as gain-of-function (GOF) hotspot missense, truncating, or other non-truncating.Results: TP53 mutations were independently associated with shorter PFS (adjusted hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.04–1.62; p = 0.019) and shorter OS in Kaplan–Meier analyses (median, 61.7 vs 91.4 months; p < 0.001). In sensitivity analyses, the association persisted in the tissue-based subset (adjusted HR, 1.55; p = 0.008), and the trend was consistent in the third-generation EGFR-TKI subset (adjusted HR, 1.26; p = 0.088). In subtype analyses, GOF and other non-truncating TP53 mutations were associated with shorter PFS (adjusted HR 1.43, p = 0.046 and 1.36, p = 0.013, respectively), whereas truncating variants were not (adjusted HR 1.03, p = 0.258).Conclusion: In EGFR-mutant NSCLC treated with first-line EGFR-TKI monotherapy, TP53 mutations—particularly GOF and non-truncating subtypes—were associated with poorer PFS and OS, supporting TP53-informed prognostic stratification.
- Open Access
- 19 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (7)
Targeting KIFC1 to disrupt centrosome clustering and trigger anaphase catastrophe in small-cell lung cancer
Supernumerary centrosomes are a hallmark of cancer. To maintain viability, cancer cells cluster these centrosomes during mitosis, enabling bipolar division similar to that of normal cells. Disruption of this centrosome clustering leads to multipolar anaphase and apoptosis (anaphase catastrophe), which selectively eliminates cancer cells harboring supernumerary centrosomes. In this context, because the motor protein KIFC1 contributes to centrosome clustering, we investigated whether targeting of this mechanism through KIFC1 inhibition could be exploited in small-cell lung cancer (SCLC), an aggressive malignancy with limited treatment options and poor prognosis. Through in silico and in vitro analyses, as well as IHC of clinical samples, we found that KIFC1 is overexpressed and that centrosome amplification occurs more frequently in SCLC compared with normal tissues and other cancer types. Pharmacological and genetic inhibition of KIFC1 disrupted the clustering of supernumerary centrosomes, triggered multipolar mitosis, and exerted antineoplastic effects in SCLC cells, with minimal effects on noncancerous cells. These findings were validated and extended in vivo using SCLC xenograft models. Finally, cotargeting KIFC1 and the centrosome duplication regulator PLK4 further enhanced growth suppression in SCLC cells. Together, these results suggest that disrupting centrosome clustering and triggering anaphase catastrophe via KIFC1 inhibition may represent a promising therapeutic strategy for SCLC.
- 19 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (7)
Open AccessTargeting KIFC1 to disrupt centrosome clustering and trigger anaphase catastrophe in small-cell lung cancer
Supernumerary centrosomes are a hallmark of cancer. To maintain viability, cancer cells cluster these centrosomes during mitosis, enabling bipolar division similar to that of normal cells. Disruption of this centrosome clustering leads to multipolar anaphase and apoptosis (anaphase catastrophe), which selectively eliminates cancer cells harboring supernumerary centrosomes. In this context, because the motor protein KIFC1 contributes to centrosome clustering, we investigated whether targeting of this mechanism through KIFC1 inhibition could be exploited in small-cell lung cancer (SCLC), an aggressive malignancy with limited treatment options and poor prognosis. Through in silico and in vitro analyses, as well as IHC of clinical samples, we found that KIFC1 is overexpressed and that centrosome amplification occurs more frequently in SCLC compared with normal tissues and other cancer types. Pharmacological and genetic inhibition of KIFC1 disrupted the clustering of supernumerary centrosomes, triggered multipolar mitosis, and exerted antineoplastic effects in SCLC cells, with minimal effects on noncancerous cells. These findings were validated and extended in vivo using SCLC xenograft models. Finally, cotargeting KIFC1 and the centrosome duplication regulator PLK4 further enhanced growth suppression in SCLC cells. Together, these results suggest that disrupting centrosome clustering and triggering anaphase catastrophe via KIFC1 inhibition may represent a promising therapeutic strategy for SCLC.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer
Matsunaga A, et al. J Gynecol Oncol. 2026 ;37:e99. https://doi.org/10.3802/jgo.2026.37.e99
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Open AccessType-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer
Matsunaga A, et al. J Gynecol Oncol. 2026 ;37:e99. https://doi.org/10.3802/jgo.2026.37.e99